Rafael Holdings Inc (RFL)
NYSEReal EstateReal Estate - ServicesSnapshot 2026-09-04
$2.56+3.64%
Close 2026-09-04 · 1-day change
NYSEReal EstateReal Estate - ServicesSnapshot 2026-09-04
QuarterlyIQ Insights · RFL
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Submit New Drug Application for Trappsol Cyclo to FDA in second half of calendar 2026 following Phase 3 trial completion and pre-NDA meeting.
Stated as a priority in 2 of last 2 quarters. Management confirmed completion of the pivotal Phase 3 TransportNPC trial with last patient last visit in June 2026 and a pre-NDA meeting with FDA completed. The NDA submission is planned for the second half of calendar 2026. This trajectory matches management's stated timeline and shows delivery on clinical milestones.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Real Estate names rated weak grew net income 54% of the time over the next year (vs 54% for the rest of the cohort, n=2778).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Expect to submit our NDA in the second half of calendar 2026 following pre-NDA meeting.”
“NDA submission and Topline data expected 2nd half 2026 after completing Phase 3 LPLV June 2026.”
Position Trappsol Cyclo as a potential commercial-stage biotechnology product targeting the high unmet need Niemann-Pick Disease Type C1 market.
Stated in 2 of last 2 quarters. Management emphasizes transitioning Rafael Holdings into a commercial-stage biotech company targeting the NPC market with high unmet need. Financials show cash and cash equivalents of $30.5 million as of April 30, 2026, supporting funding through milestones. The trajectory is consistent with management's stated commercialization focus.
“NPC represents a high-unmet-need market positioning Rafael Holdings to transition into commercial-stage biotech.”
“Focused on bringing Trappsol Cyclo to market with sufficient capital to fund through value-creating milestones.”
Strengthen IP around cyclodextrins as active pharmaceutical ingredients, including licensing patents for Alzheimer’s disease treatment in ApoE4-positive patients.
Newly stated in 2026-Q2. Management announced an exclusive licensing agreement with MIT covering cyclodextrins for treatment of ApoE4-positive Alzheimer’s disease, expanding the company’s intellectual property portfolio. This is a strategic initiative with no direct financial impact yet reported but represents a new growth avenue.
“Entered exclusive licensing agreement with MIT for cyclodextrins in ApoE4-positive Alzheimer’s disease.”
Control general and administrative expenses and increase R&D investment reflecting consolidation of Cyclo Therapeutics since March 2025 acquisition.
Stated in 1 quarter (2026-Q2). Management reported increased R&D expenses from $3.0M to $4.9M year-over-year due to Cyclo acquisition consolidation, while G&A expenses decreased from $3.2M to $2.1M due to payroll and stock compensation reductions offset by Cyclo expenses. The financials reflect management's stated expense management and investment priorities.
“R&D expenses $4.9M vs $3.0M prior year; G&A expenses $2.1M vs $3.2M prior year due to payroll and stock comp changes.”
Over the trailing year it converted 0.63x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Real Estate names rated stable grew net income 43% of the time over the next year (vs 55% for the rest of the cohort, n=685).
Not investment advice. As of 2026-09-04.